Skip to content

Study · Not a test of the peptide alone · 1995

4 results

The interaction of (1-4)-fragment of thymosin beta 4 with calmodulin-sensitive cAMP phosphodiesterase from hypothalamus.

Voelter W, Kapuzniotu A, Mihelic M, Gurvits B, Abrahamian G, Galoyan A

Neurochemical research1 Jan 1995Cited by 4 (Europe PMC)

PMID7739760 (opens in a new tab)DOI10.1007/bf00995153 (opens in a new tab)PepBankPUB-07739760
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    In lab tests, the thymosin beta‑4 (1-4) fragment caused incomplete competitive inhibition of calmodulin-stimulated hypothalamic phosphodiesterase, with an inhibition constant of 600 nM.

    In plain wordsIn lab tests, the short thymosin beta‑4 fragment partly blocked a brain enzyme that calmodulin switches on. This was not full-length thymosin beta‑4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseInhibition of calmodulin-stimulated phosphodiesterase
    Study

    n: not reported in source

    hypothalamic calmodulin-dependent cAMP phosphodiesterase
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Inhibition constant (Ki)
    600 nM
    calmodulin-stimulated phosphodiesterase

    Source sentences

    Summary
    In the course of the study of the interrelationship between the immune and neuroendocrine systems we have found that the tetrapeptide caused incomplete competitive inhibition of hypothalamic calmodulin (CaM)-dependent phosphodiesterase (PDE) stimulated by CaM.
    2 context sentences
    Summary · context
    The value of the inhibition constant (Ki) amounted to 600 nM.
    Summary · context
    It was previously shown that the N-fragment (1-4) of thymosin beta 4 (Ac-Ser-Asp-Lys-Pro-OH) inhibits in vivo the entry of cell populations into S-phase.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    In lab tests, with the thymosin beta‑4 (1-4) fragment present, the constant for phosphodiesterase activation by calmodulin rose 20-fold, with an insignificant rise in maximum rate.

    In plain wordsIn lab tests, the short fragment made the enzyme need far more calmodulin to switch on, with little change in top speed.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCalmodulin activation constant of phosphodiesterase
    Study

    n: not reported in source

    hypothalamic calmodulin-dependent cAMP phosphodiesterase
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In the presence of the peptide, the 20-fold increase of the constant for PDE activation by CaM was accompanied by an insignificant rise in the maximum rate of cAMP hydrolysis.
    1 context sentence
    Summary · context
    It was previously shown that the N-fragment (1-4) of thymosin beta 4 (Ac-Ser-Asp-Lys-Pro-OH) inhibits in vivo the entry of cell populations into S-phase.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    In lab tests without calmodulin, the thymosin beta‑4 (1-4) fragment at saturating concentrations reduced basal phosphodiesterase activity nearly 2- to 3-fold.

    In plain wordsIn lab tests without calmodulin, the short fragment lowered the enzyme's baseline activity.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseBasal phosphodiesterase activity without calmodulin
    Study

    n: not reported in source

    hypothalamic calmodulin-dependent cAMP phosphodiesterase
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In the absence of CaM, the peptide at saturating concentrations reduced the basal activity of PDE nearly 2- to 3-fold.
    1 context sentence
    Summary · context
    It was previously shown that the N-fragment (1-4) of thymosin beta 4 (Ac-Ser-Asp-Lys-Pro-OH) inhibits in vivo the entry of cell populations into S-phase.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    In lab tests, the effect of the thymosin beta‑4 (1-4) fragment on phosphodiesterase was noncompetitive with respect to cAMP.

    In plain wordsIn lab tests, the short fragment did not compete with cAMP for the enzyme.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableMode of inhibition with respect to cAMP
    Study

    n: not reported in source

    hypothalamic calmodulin-dependent cAMP phosphodiesterase
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The effect of the peptide on PDE was noncompetitive with respect to cAMP.
    1 context sentence
    Summary · context
    It was previously shown that the N-fragment (1-4) of thymosin beta 4 (Ac-Ser-Asp-Lys-Pro-OH) inhibits in vivo the entry of cell populations into S-phase.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.